Preanalgesic Effect of Gabapentin in Total Knee Repair

The recruitment status of this study is unknown because the information has not been verified recently.

Verified January 2006 by Texas Health Resources. Recruitment status was Recruiting

First Received on January 16, 2006. Last Updated on February 27, 2007 History of Changes

Sponsor:	Texas Health Resources
Information provided by:	Texas Health Resources
ClinicalTrials.gov Identifier:	NCT00279487

Purpose

The purpose of this study is to determine whether gabapentin, as a one time administration prior to a total knee replacement procedure, has opioid sparing effects and a reduction in pain scores.

Condition	Intervention
Pain	Drug: Gabapentin

Study Type:	Interventional
Study Design:	Allocation: Non-Randomized Intervention Model: Single Group Assignment Masking: Open Label

Resource links provided by NLM:

Drug Information available for: Gabapentin Gabapentin enacarbil

U.S. FDA Resources

Further study details as provided by Texas Health Resources:

Estimated Enrollment:

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

Patients undergoing total knee replacement who received pain management by the following modality:
- Intravenous patient-controlled analgesia (IV-PCA) opioid
- Local femoral nerve block with 1.5% mepivacaine 20 ml and 0.5% ropivacaine 20 ml

Exclusion Criteria:

Age < 18 years old

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00279487

Contacts

Contact: Rob Hutchison, PharmD

214-345-2493

robhutchison@texashealth.org

Locations

United States, Texas
Presbyterian Hospital of Dallas	Recruiting
Dallas, Texas, United States, 75231
Contact: Rob Hutchison 214-345-2493 robhutchison@texashealth.org
Contact: Denise Stamos 214-345-2966 denisestamos@texashealth.org
Principal Investigator: William Tucker
Sub-Investigator: Jeffrey Pirinelli
Sub-Investigator: Joy Aguwa

Sponsors and Collaborators

Texas Health Resources

Investigators

Principal Investigator:

Rob Hutchison

Texas Health Resources

More Information

No publications provided

ClinicalTrials.gov Identifier:	NCT00279487 History of Changes
Other Study ID Numbers:	P768
Study First Received:	January 16, 2006
Last Updated:	February 27, 2007
Health Authority:	United States: Institutional Review Board

Keywords provided by Texas Health Resources:

Patients undergoing total knee replacement who received pain management by the following modality:
IV PCA opioid
Local femoral nerve block with 1.5% Mepivacaine & 0.5% Ropivacaine

Additional relevant MeSH terms:

Gabapentin
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Pharmacologic Actions
Central Nervous System Agents
Therapeutic Uses
Anticonvulsants
Antiparkinson Agents
Anti-Dyskinesia Agents
Calcium Channel Blockers

Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Cardiovascular Agents
Anti-Anxiety Agents
Tranquilizing Agents
Central Nervous System Depressants
Psychotropic Drugs
Excitatory Amino Acid Antagonists
Excitatory Amino Acid Agents
Neurotransmitter Agents
Antimanic Agents

ClinicalTrials.gov processed this record on February 13, 2012